Domestic anti-cancer drug major Dabur Pharma is finalising plans to enter Japan and China. The company has started the groundwork of filing drug applications and is scouting for potential pharma acquisitions in both the countries.
Dabur Pharma also plans to expand the range of products developed on its nanotechnology drug delivery system, christened â€˜Nanoxel\'. At the moment, it sells the popular anti-cancer drug â€˜Paclitaxel\' on this platform. \"We also want to export this portfolio of drugs in US, Europe and South-east Asian markets,\" said Mr Vij.